Type 2 diabetes MedDRA version: 9.1 Level: LLT Classification code 10045242 Term: Type II diabetes mellitus
Conditions
Interventions
Trade Name: Acetylsalicylzuur Neuro 30 mg
Pharmaceutical Form: Tablet
Trade Name: Aspirine 100
Pharmaceutical Form: Tablet
Sponsors
Academic Medical Centre
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Age > 18 years Diagnosis of type 2 diabetes according to ADA criteria Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Current acetylsalicylic acid therapy Use of any medication interfering with platelet function, e.g. diclofenac, naproxen or clopidogrel in the two weeks prior to the study. Abnormal platelet count Allergy or hypersensitivity to prostaglandinsynthetase inhibitors Hemorrhagic stroke in medical history Gastric complaints or gastritis/ulcus pepticum, history of gastric bleeding Severe liver or kidneyfailure
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To determine whether laboratory acetylsalicylic acid resistance is more prevalent in type 2 diabetic patients with poor glycaemic control as compared to type 2 diabetic patients with adequate or intermediate glycaemic control and healthy subjects.;Secondary Objective: To determine whether higher doses of acetylsalicylic acid can overcome laboratory acetylsalicylic acid resistance in type 2 diabetic patients.;Primary end point(s): Prevalence of laboratory acetylsalicylic acid resistance in type 2 diabetic patients stratified by level of glycaemic control. | — |
Countries
Netherlands
Outcome results
None listed